Ratings for DexCom (NASDAQ:DXCM) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It’s the longest-lasting wearable on the market. The G7 15 ...
In the preceding three months, 12 analysts have released ratings for DexCom (NASDAQ:DXCM), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the ...
This is a Class I recall where 56 serious injuries have been reported. If you use one of Dexcom's continuous glucose monitoring systems, here's what you need to know. Some of Dexcom’s continuous ...
Though it received a green light in Europe this past March, Dexcom will resubmit the G7 CGM's software for FDA review after making changes to how it delivers glucose alerts. (Dexcom) Diabetes tracker ...
Type 2 diabetes patients who take a GLP-1 such as Ozempic or Wegovy are associated with higher usage of continuous glucose monitors, Dexcom said Sept. 5, according to an Investor’s Business Daily ...
Argus Adjusts Price Target on DexCom to $96 From $86, Maintains Buy Rating MT Aug. 03 UBS Adjusts Price Target on DexCom to $102 From $96, Maintains Buy Rating MT Aug. 03 Rothschild & Co Redburn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results